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Abstract  
The use of data from multiple studies or centers for the validation of a clinical test or a 
multivariable prediction model allows researchers to investigate the test’s/model’s performance 
in multiple settings and populations. Recently, meta-analytic techniques have been proposed to 
summarize discrimination and calibration across study populations. Here, we rather consider 
performance in terms of Net Benefit, which is a measure of clinical utility that weighs the 
benefits of true positive classifications against the harms of false positives. We posit that it is 
important to examine clinical utility across multiple settings of interest. This requires a suitable 
meta-analysis method, and we propose a Bayesian trivariate random-effects meta-analysis of 
sensitivity, specificity, and prevalence. Across a range of chosen harm-to-benefit ratios, this 
provides a summary measure of Net Benefit, a prediction interval, and an estimate of the 
probability that the test/model is clinically useful in a new setting. In addition, the prediction 
interval and probability of usefulness can be calculated conditional on the known prevalence in a 
new setting. The proposed methods are illustrated by two case studies: one on the meta-analysis 
of published studies on ear thermometry to diagnose fever in children, and one on the validation 
of a multivariable clinical risk prediction model for the diagnosis of ovarian cancer in a 
multicenter dataset. Crucially, in both case studies the clinical utility of the test/model was 
heterogeneous across settings, limiting its usefulness in practice. This emphasizes that 
heterogeneity in clinical utility should be assessed before a test/model is routinely implemented.  
 
Keywords: meta-analysis, net benefit, test accuracy, diagnostic, decision curves 
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1. Introduction 
Clinical diagnoses are often predicted using tests and multivariable prediction models that 
combine various predictors.
1
 Before diagnostic tests or models are introduced into clinical 
practice, it is of the utmost importance that their predictive performance is externally validated on 
new data. This preferably takes place in a setting that is independent from the test’s or model’s 
development setting, for example in new centers or by other research teams.
2
 Typically, 
researchers assess the discriminative ability of the test/model to distinguish between patients who 
do and do not suffer from the suspected disease. These results are summarized using, among 
others, sensitivity, specificity, and the c-statistic. If the diagnostic tool yields a predicted risk that 
the patient suffers from the disease, measures of calibration can be used, which assess how well 
predicted risks correspond to observed event rates.
3
  
A problem with measures of discrimination and calibration is that they do not assess the 
consequences of using a test/model in practice. In contrast, decision-analytic measures of clinical 
utility incorporate the harms of false negative and false positive classifications. A measure of 
clinical utility that has received broad support is the Net Benefit (NB).
4-8
 Briefly, the NB 
quantifies the benefit of using a test/model for clinical decision making by correcting the number 
of true positive classifications for the number of false positive classifications using a weighting 
factor.
9,10
 The weight reflects the ratio of the harm of a false positive and a false negative. 
Because the assumed harms can vary, the NB is usually calculated for a relevant range of harm 
ratios. A plot of the NB for various harm ratios is a decision curve.  
All measures of clinical utility depend on disease prevalence,
11
 which may vary across studies, 
centers, and regions. In addition, the predictive performance of a test/model may be 
heterogeneous, reflecting differences in patient case-mix or true variations in the association 
between predictors and the disease.
1,12,13
 Recently, meta-analytic techniques have been proposed 
to investigate heterogeneity in predictive performance (discrimination and calibration) across 
populations.
14,15
 The NB is influenced by an interplay of the prevalence of the outcome, 
discrimination, and calibration. Although heterogeneity in clinical utility may naturally be 
expected, methods for the meta-analysis of the clinical utility of a test/model have not been 
considered. Indeed, before routinely implementing a test/model in practice, it is surely essential 
to examine its clinical utility across multiple settings of interest. To address this, we consider a 
method for the meta-analysis of the NB, using a Bayesian trivariate random-effects meta-analysis 
of sensitivity, specificity, and prevalence.  
In what follows, we introduce two motivating examples. The first concerns diagnosing fever in 
children, and investigates the clinical usefulness of using ear thermometry based on a systematic 
review of the literature. The second is a multicenter external validation of the clinical utility of 
the IOTA LR2 model, which is a multiple logistic regression model based on ultrasound 
characteristics to distinguish between benign and malignant adnexal masses. In Section 3 we 
introduce the NB measure of clinical utility, and explain how to calculate it from a trivariate 
random-effects meta-analysis of sensitivity, specificity, and prevalence. Bayesian prediction 
intervals may be used to predict the clinical utility in randomly selected new studies or centers. 
We propose to construct prediction intervals conditional on a known prevalence, if this 
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information is available in a new setting. We apply these ideas to our examples in Section 4. In 
section 5 we put the NB of the test/model into perspective by comparing it to other diagnostic 
strategies, such as the default strategies that classify all patients as positive or negative. We show 
how to graphically present the comparison using decision curves, and introduce the Bayesian 
probability that the test/model performs better than the default strategies in a randomly selected 
new setting. 
2. Two motivating examples 
2.1. Meta-analysis of the clinical utility of ear temperature for diagnosing fever in 
children 
Rectal temperature measurement can be difficult in children, particularly when they are 
uncooperative or restless. Ear thermometry is a commonly used and attractive alternative, as the 
ear is easily accessible and the procedure is very quick. Craig and colleagues performed a 
systematic review of the accuracy of infrared ear thermometry for diagnosing fever in children.
16
 
They retrieved eleven studies evaluating the accuracy of ear thermometers of the ‘FirstTemp’ 
brand. All studies considered patients with an ear temperature ≥38.0 °C as test positive, and the 
gold standard diagnosis of fever was a rectal temperature ≥38.0 °C. The number of children with 
(n1) and without (n0) fever, and the number true positive (r11) and true negative (r00) 
classifications per study j are summarized in Table 1. The observed prevalence of fever as 
diagnosed by the gold standard varied between 27% and 75%, reflecting that the studies included 
children who were already in a hospital or an emergency unit. 
A random-effects meta-analysis of the discriminative performance has already been performed, 
yielding a summary sensitivity of 65% and a summary specificity of 98%, and demonstrating 
considerable between-study heterogeneity, especially in sensitivity.
15
 We may now ask the 
question whether using ear thermometry to diagnose fever is clinically useful to inform patient 
management and treatment decisions. On the one hand, one may want to avoid missing serious 
infectious diseases in young children, and stress the harm of a false negative classification. In this 
case, sensitivity is important, and the test accuracy does not appear satisfactory in most studies 
(Table 1). On the other hand, one may want to avoid overtreatment of fever and unnecessary 
hospitalization costs, when the child can be safely taken care of at home. In this case, specificity 
is important, and this was very good (Table 1), despite heterogeneity across settings. To make 
any statement regarding the likely clinical usefulness of ear thermometry in a new population, a 
random-effects meta-analysis of the NB is required. Such an analysis directly takes into account 
the relative harms of false positive and false negative classifications. 
2.2. Multicenter validation of a diagnostic multivariable risk model for diagnosing 
ovarian cancer 
The LR2 model is a logistic regression model based on ultrasound characteristics to obtain a pre-
operative diagnosis of ovarian cancer, yielding a predicted probability of malignancy.
17
 Testa et 
al. performed a multicenter validation study of the predictive performance of the LR2 model, 
which included 2403 patients from 18 centers. All patients were selected for surgical removal of 
an adnexal mass and histology was the reference standard to diagnose cancer.
17
 The predicted 
probabilities of malignancy for cancer cases and healthy patients in the validation dataset are 
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shown per center in Figure 1, for the 15 largest centers. The observed prevalence of malignancy 
varied between 15% and 69%. 
A meta-analysis in the included centers yielded a summary c-statistic of 0.92 with little between-
center heterogeneity, demonstrating excellent discrimination between benign and malignant 
tumors.
17
 However, Testa et al. showed that the LR2 model tends to underestimate the probability 
of malignancy in most centers, that is, there was some miscalibration of the model’s 
predictions.
17
 To conclude whether or not the LR2 model is clinically useful in new centers 
despite the miscalibration, it is required to perform a random-effects meta-analysis of the NB. 
This takes into account the harms of missing a cancer and the harms of unnecessarily referring a 
patient without cancer for specialized oncology care based on a predefined risk threshold. 
Figure 1. Density plots of predicted probabilities of ovarian cancer from the LR2 model, per 
center. Plot headings indicate the center’s location, number of patients and number of cancer 
cases. 
[insert figure 1 here] 
3. Investigating heterogeneity in the Net Benefit of a test/model using meta-analysis 
3.1. Net Benefit 
Unlike traditional measures of predictive performance, NB incorporates the consequences of 
using the test/model to guide clinical decision making. The method assumes that there is a risk 
threshold, t, at which one is uncertain about treating or not treating a patient. If P(disease)<t, the 
patient should forego treatment, whereas the patient should receive treatment if P(disease)≥t. The 
relative consequences of falsely treating a patient without disease versus falsely withholding 
treatment from a patient with disease are implied by t: odds(t) is the ratio of the harm associated 
with a false positive result and the harm associated with a false negative result.
10
 For example, if 
a risk threshold of 0.20 is used, the harm ratio is 1:4. The harm of a false negative is four times 
larger than the harm of unnecessary treatment. This implies that unnecessarily treating up to four 
patients for each correctly treated patient is considered acceptable. Odds(t) can also be thought of 
as a ‘harm-to-benefit’ ratio. Indeed, the harm of a false negative equals the forgone benefit of 
being rightly treated. 
NB corrects the number of true positives (r11) for the number of false positives (r01) weighted by 
the harm ratio (odds(t)), and divides the result by the total sample size (n):
10
 
(1) 
NBt =
r11−(r01×
t
1−t
)
n
. 
NBt quantifies benefit in terms of the net proportion of true positives at threshold t. If we evaluate 
a risk prediction model that yields predicted probabilities, r11 and r01 vary with the chosen risk 
threshold (and hence the harm ratio), as we classify patients with a predicted risk >t as positive. If 
we are evaluating a binary diagnostic test, r11 and r01 are constant but the harm ratio can still be 
varied.
18
 Reasonable choices for the harm ratio reflect differences in risk aversion (the highly risk 
averse prefer a lower threshold) and/or health care systems. For example, when long waiting lists 
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for treatment are a reality, higher risk thresholds may be adopted. Note that NBt should not be 
used to select the risk threshold t.
4
 Rather, for a given t, reflecting a certain harm ratio, we can 
find out whether a test/model is clinically useful. 
NBt can also be computed for default strategies where either everyone is treated or no one is 
treated.  In fact, for ‘treat none’, r11=r01=0, hence NBt treat none=0 by definition. If NBt of a 
test/model is higher than the NBt of ‘treat all’ or ‘treat none’, the test/model is considered useful 
at threshold t. We will elaborate on these comparisons in section 5. In the next sections, we first 
consider a meta-analysis of the NBt. 
3.2. A trivariate meta-analysis model of the true positive rate, true negative rate and 
prevalence 
3.2.1. Trivariate meta-analysis 
The NBt is a function of classification results and the risk threshold. Hence, in a meta-analysis, 
the summary NBt can be computed from summary measures of prevalence, sensitivity, and 
specificity, at a given risk threshold.  
Suppose data from J (j=1 to J) settings are available. We will use the term ‘setting’ throughout 
this work to refer to a single center in a multicenter study, or to a single study in the meta-
analysis of multiple published studies. Each has n1j and n0j patients with and without the disease 
(or other outcome of interest), respectively, and n1j+n0j=nj. In setting j, at a chosen risk threshold, 
the test or model under validation yields a positive classification for r11j patients with the disease 
(true positives), and a negative classification for r00j patients without the disease (true negatives). 
The observed sensitivity in each setting is r11j/n1j and the observed specificity is r00j/n0j. To 
combine this information across settings, a trivariate random-effects meta-analytic model for 
prevalence, sensitivity, and specificity has been proposed previously.
19
 Assume a binomial 
distribution for the number of patients with the disease or outcome, the number of true positives, 
and the number of true negatives in each setting: 
(2) 
n1j~bin (nj,pj) 
r11j~bin(n1j,Sej) 
r00j~bin (n0j,Spj). 
After applying the logit transformation, the true setting-specific prevalences (pj), sensitivities 
(Sej), and specificities (Spj) are assumed to be normally distributed with means γ1, γ2, and γ3. The 
variance-covariance matrix Ω contains the between-setting variance in the logit prevalence (τ1
2), 
the logit sensitivity (τ2
2), and the logit specificity (τ3
2), and the covariances. Hence, we account 
for the heterogeneity and the correlations between the logit prevalence and the logit sensitivity 
(ρ
12
), the logit prevalence and the logit specificity (ρ
13
), and the logit sensitivity and the logit 
specificity (ρ
23
): 
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(3) 
(
 
 
logit (p
j
)
logit(Sej)
logit (Sp
j
)
)
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γ
3
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1
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τ3
ρ
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1
τ2 τ2
2 ρ
23
τ
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ρ
13
τ
1
τ3 ρ23τ2
τ3 τ3
2
)
 . 
The summary NBt can now be estimated from γ1, the summary logit prevalence, γ2, the summary 
logit sensitivity, γ3, the summary logit specificity, and t, as follows: 
(4) 
NBt =
exp(γ2)
1 + exp(γ2)
×
exp(γ1)
1 + exp(γ1)
− [(1 −
exp(γ3)
1 + exp(γ3)
) × (1 −
exp(γ1)
1 + exp(γ1)
) ×
t
1 − t
]. 
The process can be repeated for each threshold (i.e., at each threshold apply a trivariate meta-
analysis of sensitivity, specificity, and prevalence, and then use equation (4) to obtain the NBt). 
The trivariate model of sensitivity, specificity, and prevalence can be estimated using a 
frequentist or Bayesian approach. We prefer a Bayesian approach, because it yields an estimate 
of the posterior probability distribution of the NBt that accounts for all parameter uncertainty and 
naturally enables subsequent predictions of the NBt in new settings. However, it also requires the 
specification of prior distributions. We used a vague multivariable normal prior distribution for 
the vector of logit prevalence, logit sensitivity and logit specificity, with mean 0, variances 1000, 
and covariances 0. An inverse Wishart prior was used for the between-setting variance-
covariance matrix Ω, with variances 10, covariances 0, and the number of degrees of freedom as 
small as possible (3, the number of outcomes) to reflect vague prior knowledge. However, it has 
been shown that seemingly vague Wishart priors may still be influential, which can affect 
posterior inferences for the between-setting variances, correlations, and pooled summary 
estimates.
20-22
 Therefore, in the next section, an alternative product normal parametrization of the 
model is introduced, which allows specifying priors for all elements of the variance-covariance 
matrix separately. 
3.2.2. Alternative product normal parametrization of the between-setting model. 
The between-setting model (3) can be reparametrized in the product normal formulation, as 
proposed by Bujkiewicz et al.
21,23
 This formulation models the true logit prevalence, the true logit 
sensitivity and the true logit specificity as conditional univariate normal distributions, using linear 
models for the relations between them: 
(5) 
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{
 
 
 
 
 
 
 
 logit (pj) ~N(η1,ψ1
2 )
logit(Sej)|logit (pj)~N (η2j,ψ2
2 )
η
2j
=λ20+λ21logit (pj)
logit (Sp
j
) |logit (p
j
) , logit(Sej)~N (η3j,ψ3
2 )
η
3j
=λ30+λ31logit (pj)+λ32logit(Sej).
 
Instead of specifying a prior distribution for the between-setting variance-covariance matrix Ω as 
a whole, this formulation allows us to place realistic prior distributions on separate elements of 
Ω. Hence, this formulation eases the incorporation of prior information on the between-setting 
standard deviations and correlations obtained from previous studies or published literature. If this 
information is not available, realistic weak priors can be used, such as weak Fisher priors for 
correlations, which restrict correlations between -1 and 1, and weak half-normal priors for 
variances, which are bounded by zero.
20,21
 The implied prior distributions on the parameters λ21, 
λ31, and λ32, and the hyper-parameters ψ1, ψ2, and ψ3 are dictated by the relationships between 
these parameters and the elements of the between-setting variance-covariance matrix, which have 
been derived by Bujkiewicz and colleagues: 
(6) 
ψ
1
2 = τ1
2,  ψ
2
2 = τ2
2 − λ21
2
τ1
2,  ψ
3
2 = τ3
2 − λ31
2
τ1
2 − λ32
2
τ2
2 
λ21 =
τ2
τ1
ρ
12
,   λ31 =
τ3
τ1
ρ
13
− λ32λ21,    λ32 =
ρ
23
 τ2τ3 − ρ13 τ1τ3λ21
τ2
2 − λ21
2
τ1
2
. 
The remaining parameters can be given vague prior distributions, for example, η1~N(0,1000), 
λ20~N(0,1000), λ30~N(0,1000). The summary logit prevalence, logit sensitivity, and logit 
specificity are directly linked to the re-parametrized model formulation: 
(7) 
γ
1
= η
1
 
γ
2
= λ20+λ21γ1 
γ
3
=λ30+λ31γ1+λ32γ2. 
Hence, the summary NBt can be computed based on γ1, the summary logit prevalence, γ2, the 
summary logit sensitivity, γ3, the summary logit specificity, and t, the risk threshold of interest, as 
in equation (4). 
3.3. Net Benefit for a new population 
3.3.1. 95% prediction intervals 
In the presence of between-study (or between-center) heterogeneity in disease prevalence or 
predictive performance, the summary NBt is potentially inadequate to quantify the expected NBt 
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in a new study (or center). A 95% prediction interval for the NBt in a new setting reveals the 
potential impact of heterogeneity on the clinical utility in new settings. A 95% prediction interval 
for NBt can be obtained in a natural way in a Bayesian framework, by sampling sensitivity, 
specificity, and prevalence for new studies (or centers) from their joint posterior distribution. 
Hence, the uncertainty in all parameters estimated in the meta-analytic model is propagated when 
deriving predictions for the NBt in a new setting.  
3.3.2. Prediction intervals using prior knowledge on the prevalence in the new setting 
The product normal formulation of the between-setting model allows an elegant prediction of 
NBt in a new setting, conditional on a known prevalence, using the posterior estimates of lambda 
parameters: 
(8) 
γ̂2 = λ̂20+λ̂21logit(prevalence) 
γ̂3=λ̂30+λ̂31logit(prevalence)+λ̂32γ̂2 
NB̂t|prevalence =
exp(γ̂2)
1+exp(γ̂2)
× prevalence − [(1 −
exp(γ̂3)
1+exp(γ̂3)
) × (1 − prevalence) ×
t
1−t
]. 
The prevalence can be treated as known a priori, or given a distribution reflecting uncertainty in 
the prevalence estimate. By sampling from the posterior distribution, uncertainty in all 
parameters is accounted for in the prediction interval of the NBt at a given prevalence, while the 
interrelations between prevalence, sensitivity, and specificity are accounted for. When a Wishart 
prior is used instead of the product normal formulation, the sensitivity and specificity of a new 
setting can be sampled and combined with the prevalence to obtain the predicted NBt. 
3.4. Implementation in WinBUGS 
The models were implemented in WinBUGS. The estimates were obtained using MCMC 
sampling with 2 chains of 100 000 iterations, excluding a burn-in of 50 000, and using a thinning 
factor of 20. The convergence was checked visually by monitoring the chains for the parameters 
of interest (i.e., sensitivity, specificity, prevalence, NBt, τ1
2, τ2
2, τ3
2 , NBt | prevalence, and NBt treat 
all (see section 5). The NBt, NBt | prevalence, and NBt treat all were monitored separately for 
settings in the sample and new settings sampled from the joint posterior of sensitivity, specificity 
and prevalence to obtain prediction intervals). The model syntax is included in Web Appendix 1 
and 2. Summary estimates of NBt are reported as posterior means with 95% credible intervals and 
95% prediction intervals. 
4. Application to the two case studies 
In what follows, the NBt is computed for using the in-ear thermometer to diagnose fever and for 
the LR2 model to diagnose ovarian cancer. The results we present are the results of the product 
normal formulation, using realistic priors for the between-study (between-center) variance-
covariance matrix. Comparisons with the results obtained when using the Wishart distribution are 
presented in Appendix Table 2 and Appendix Table 3. 
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4.1. Meta-analysis of the clinical utility of ear temperature for diagnosing fever in 
children 
The NBt of using an ear thermometer was calculated at three risk thresholds: 0.2, 0.5, and 0.8. A 
risk threshold of 0.2 indicates that we would be willing to diagnose 4 healthy children with fever 
to detect one true positive case. A risk threshold of 0.5 indicates that we believe the harm of a 
false positive is equal to the harm of a false negative. A risk threshold of 0.8 indicates that we 
perceive the harm of a false positive to be 4 times larger than the harm of a false negative. We 
selected these risk thresholds for illustrative purposes and assume they reflect different opinions 
regarding the perceived relative harms of false positive and false negative diagnoses of fever 
clinicians may hold. 
We used Fisher priors (z~N(-0.20, 0.50
2
), with z=log((1+ ρ)/(1- ρ))) for the correlations between 
logit sensitivity and logit specificity (ρ
23
), and logit specificity and logit prevalence (ρ
13
). The 
chosen prior distribution corresponds to a moderate negative correlation (Appendix Figure 1) to 
reflect prior knowledge on spectrum bias, the phenomenon that the performance of a test or 
model differs between clinical settings due to case-mix differences. Referral patterns may lead to 
higher sensitivities and lower specificities in high-prevalence settings.
24
 Leeflang found empirical 
evidence for a negative correlation between specificity and prevalence, indicating that differences 
in prevalence may represent changes in the spectrum of people without the disease of interest.
25
 
People with symptoms or prior test results indicative of the disease may be referred to certain 
centers, yielding at the same time a higher prevalence and a group of patients without the disease 
that are harder to diagnose correctly. For the correlation between logit sensitivity and logit 
prevalence (ρ
12
), a uniform prior (U[-0.99, 0.99]) was used, as previous empirical research could 
not demonstrate an overall positive or negative correlation relation between sensitivity and 
prevalence.
25
 We used a half-normal prior distribution for the between-setting variance of logit 
sensitivity, logit specificity, and logit prevalence, τ1 (2,3)
2 ~N(0, 22)I(0, ) (see Appendix Figure 1).  
Arbitrary but plausible initial values were manually set for some key parameters to facilitate 
convergence (η1: 0.45, λ20: 0.7, λ30: 0.08, Z(ρ12): 0, Z(ρ13): 0, Z(ρ23): 0, the between-setting 
variance of sensitivity: 0.31, the between-setting variance of specificity: 0.47, and between-
setting variance of prevalence: 0.2). The initial values for remaining parameters in the model 
were randomly sampled from the prior distributions, using the “gen inits” function in WinBugs. 
In the case of vague priors, this function generates extreme initial values. 
Recall that children with an ear temperature ≥38.0 °C were classified as having fever, and 
children with an ear temperature <38.0 °C were classified as not having fever, regardless of t. 
This yielded a summary sensitivity of 65%, and a summary specificity 98%. When the risk 
threshold was 0.2, reflecting larger perceived harms of false negatives than false positives, the 
summary NB0.2 was 0.30 (95% CrI 0.19 to 0.42). This indicates that the net benefit of this 
diagnostic test is equivalent to the benefit of correctly classifying a net number of 30 children 
with fever per 100 patients, and no false positive classifications (Table 2). In section 5, we will 
give an interpretation that puts the magnitude of this value into perspective. The prediction 
interval reveals there is a 95% probability that NB0.2 will be between 0.03 and 0.68 in a new 
study. For a new study with a prevalence of fever of 50%, we find a summary NB0.2 of 0.32 and a 
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narrower prediction interval of 0.12 to 0.47, reflecting that we now have information on the 
prevalence, which restricts the likely values of NBt in the new setting.  
If we compute the NBt at higher risk thresholds, indicating equal or lower perceived harms for 
false negatives than for false positives, the summary NBt is lower. This reflects the increasing  
correction for the number of false positives. Results for risk thresholds 0.5 and 0.8 are given in 
Table 2.  
Similar point estimates with generally narrower credible intervals were obtained when inverse 
Wishart priors were used for the between-study variance-covariance matrix, but small differences 
were observed, especially for NBt at t=0.8 (see Appendix Table 2). 
Sensitivity to the choice of initial values was checked by repeating the analysis with widely 
separated starting values for the two chains (η1: -2.2 versus 2.2 , λ20: -2.2 versus 2.2, λ30: -2.2 
versus 2.2, ρ12: 0 versus 0.9, Z(ρ13): 0 versus -1.47, Z(ρ23): 0 versus -1.47, the between-setting 
variance of sensitivity: 0.1 versus 5, the between-setting variance of specificity: 0.1 versus 5, and 
between-setting variance of prevalence: 0.1 versus 5). All chains started mixing in the first 300 
iterations and converged to summary estimates that were very similar to the ones reported. 
4.2. Multicenter validation of a diagnostic multivariable risk model for ovarian cancer 
The NBt of the LR2 model for diagnosing ovarian cancer was calculated at three risk thresholds: 
0.05, 0.1, and 0.5. The low risk thresholds indicate the need for a diagnostic strategy with a high 
sensitivity for malignancy, and perceived harms of false negatives that are at least as high as the 
perceived harms of false positives. In clinical reality, risk thresholds above 0.5 are not sensible 
because this would imply that a false positive case (unnecessarily being referred to specialized 
oncology care to undergo additional MRI testing) is more harmful than a false negative (an 
undetected cancer). 
In this analysis, we used the posterior probability distributions obtained from the analysis of 
another validation study of the LR2 model (n=1938) as prior distributions in the current 
analysis.
26,27
 This external dataset contained data from 19 centers (12 of which also contributed 
data to the current dataset), and was collected at an earlier time. The external dataset was 
analyzed using weak realistic priors (the same as in section 4.1). We characterized the resulting 
posterior distributions by their means and standard deviations (which varied with t as shown in 
Appendix Table 1), and chose parametric distributions to match their shapes. We used normal 
distributions for η1, λ20, and λ30, lognormal distributions for the between-center variance of logit 
sensitivity, logit specificity, and logit prevalence, and normal distributions for the Fisher 
transformations of the correlations. The resulting distributions were used as prior distributions in 
the current analyses. 
To facilitate convergence, the means of the posteriors obtained in the external datasets were used 
to set initial values for some key parameters (η1, λ20, λ30, Z(ρ12), Z(ρ13), Z(ρ23), and the 
between-setting variance of sensitivity, specificity, and prevalence). The initial values for 
remaining parameters in the model were randomly sampled using the “gen inits” function in 
WinBugs. 
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Because the number of patients classified as test positive decreases as the adopted risk threshold 
increases, the summary sensitivity decreases from 0.95 at t=0.05 to 0.63 at t=0.5, and the 
summary specificity increases from 0.68 at t=0.05 to 0.95 at t=0.5 (Table 3). At a risk threshold 
of 0.05, the summary NB0.05 is 0.27 (95% CrI 0.21 to 0.34). Hence, the net benefit of the model is 
equivalent to the benefit of a strategy that correctly detects a net number of 27 cancer cases per 
100 patients, without false positive classifications. A more complete interpretation is given in 
section 5. The heterogeneity in NB0.05 between centers is quite large, as reflected by the 95% 
prediction interval: 0.05 to 0.66. A more precise prediction of the NB0.05 in a new center may be 
obtained by conditioning on a known prevalence. Regional centers typically have a lower cancer 
prevalence than university hospitals with a specialized gynecological oncology unit. For new 
center with a known prevalence of 15%, the NB0.05 lies between 0.12 and 0.14 with 95% 
certainty. For a new center with a known prevalence of 35%, the NB0.05 lies between 0.29 and 
0.33 with 95% certainty.  
With higher risk thresholds, the NBt is lower, reflecting that by adopting these perceived harm 
ratios gradually more weight is given to false positive classifications (Table 3). 
The point estimates, 95% credible intervals and 95% prediction intervals were influenced by the 
choice of prior for the variance-covariance matrix, but differences nearly disappeared when NBt 
was estimated conditional on a known prevalence in a new setting (see Appendix Table 3). 
Credible intervals were often wider when the Wishart prior was used. 
5. Putting the Net Benefit into perspective: is the test/model clinically useful? 
5.1. The probability that a test/model is clinically useful in a new setting 
The NBt of a test/model is usually compared to the NBt of ‘treat all’ and ‘treat none’. The NBt of 
treat all equals p-[(1-p)×t/(1-t)], with p the prevalence of the disease, while the NBt of treat none 
equals 0, irrespective of t. Similar to NBt of a test/model, NBt of ‘treat all’ may vary between 
settings, because it is dependent on the prevalence. By sampling from the posterior distribution of 
the prevalence, the summary NBt of treat all and a 95% prediction interval can be obtained in the 
Bayesian random-effects meta-analytic framework outlined above. By using a priori knowledge 
on the prevalence, we can also calculate the NBt of treat all in a new setting with the given 
prevalence. 
If the NBt of the test/model of interest is below that of treat all or treat none, the test/model is 
harmful, because decisions made without use of the test/model have higher clinical utility.
9,10
 In 
contrast, if the NBt of the test/model of interest higher than that of treat all and treat none, the 
test/model is clinically useful: 
(9) 
P(useful)=P[NBt>max(NBt treat all, 0)] . 
In the Bayesian framework, we can sample from the joint posterior distribution of sensitivity, 
specificity and prevalence, and evaluate in each sample whether the NBt of the test/model in a 
new setting is larger than the NBt of treat all and treat none. Hence, we obtain the probability that 
the test/model is useful in any new setting. By using a priori knowledge on the prevalence, we 
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can also calculate the probability that the test/model is clinically useful in a new setting with the 
given prevalence. 
At a risk threshold of 0.2, treat all is the best default strategy for fever, with a NB0.2 of 0.33 (95% 
CrI 0.20 to 0.46). At the 0.5 and 0.8 risk thresholds, the summary NBt of treat all is <0, making 
treat none the best default strategy (Table 4). Nonetheless, there is considerable heterogeneity in 
the NBt of treat all in new studies, reflecting heterogeneity in prevalence. For example, at t=0.5, 
the 95% prediction interval is -0.65 to 0.57. The probability that using an in-ear thermometer is 
better than the two default strategies of diagnosing fever in all or none of the children depends on 
the adopted risk threshold. At t=0.2 (i.e., a harm ratio of 1:4) there is a 44% chance that using an 
ear thermometer is clinically useful in any new setting, and a 34% chance that this strategy is 
clinically useful in a setting with a known prevalence of fever of 0.50. However, if we assume 
that false positive and false negative diagnoses are equally bad (t=0.5), there is a 97% chance that 
using an in-ear thermometer is clinically useful in any new setting, and a 99.9% chance that this 
strategy is clinically useful in a setting with a known prevalence of fever of 0.50. At t=0.8, the 
probability of usefulness in any new setting is 95%, and the probability of usefulness in a new 
setting with a prevalence of 0.50 is 99%.  
The best default strategy to diagnose ovarian malignancy at risk thresholds 0.05 and 0.1 is treat 
all (NB0.05 0.26, 95% CrI 0.20 to 0.34; NB0.1 0.22, 95% CrI 0.15 to 0.30), while it is treat none at 
t=0.5 (Table 5). Here too, the between-center heterogeneity in the NBt of treat all is large, with 
the 95% prediction interval at t=0.05 ranging from 0.02 to 0.69. If the perceived harms of false 
negatives are 19 times larger than the perceived harms of false positives (t=0.05), there is a 69% 
chance that LR2 is useful in any new center. The probability of usefulness is 99.9 % in a center 
with a malignancy rate of 15%. Interestingly, if the malignancy rate is 35%, the probability that 
LR2 is useful is lower: 75%. This is likely due to the miscalibration of LR2, which seemed to be 
especially pronounced in centers with a high prevalence.
17
 The probabilities that the LR2 model 
is useful to diagnose ovarian cancer in a new center when risk thresholds 0.1 or 0.5 are adopted 
are given in Table 5. 
The summary estimates, 95% credible intervals and 95% prediction intervals of the NBt for treat 
all were influenced by the choice of prior in both case studies (see Appendix Table 2 and 
Appendix Table 3). The probability of usefulness was also influenced by the choice of prior; the 
biggest difference was observed in the fever case study with t=0.2 (0.31 with the Wishart prior 
versus 0.44 with the realistic weak informative priors). 
A straightforward extension of the proposed methods to quantify the probability of clinical utility 
in new settings is to include a routinely suggested competitor test/model in the comparison. One 
may want to quantify the probability that the model/test of interest performs better than the 
routinely used test/model and both default strategies: P[NBt > max(NBt routinely used model/test, NBt treat 
all, 0)]. Routinely used competitor models/tests may be the temperature taken in the mouth or 
under the arm for the first example, and the RMI algorithm for ovarian cancer in the second 
example.
17,26,27
 
5.2. Decision curves 
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A decision curve is a plot of the NBt of a test/model and the NBt of default strategies for a range 
of relevant risk thresholds, and allows an easy graphical comparison of diagnostic strategies.
10
 In 
the Bayesian framework outlined above, the NBt, pointwise credible intervals and pointwise 
prediction intervals can be computed for each risk threshold of interest, and subsequently plotted 
and connected, as in Figure 2 below for the fever example and Figure 3 below for the ovarian 
cancer example.  
In the first example, it is immediately clear that the summary NBt of infrared ear thermometry 
(blue curve) is below the summary NBt of treating all patients (purple curve) up to risk threshold 
0.23. For higher risk thresholds, the summary NBt of using an ear thermometer is higher than the 
summary NBt of both default strategies. The large between-study heterogeneity in NBt  is 
reflected by the broad prediction intervals around the summary curves (light transparent bands). 
The large heterogeneity makes it impossible to visually assess whether ear thermometry will have 
clinical utility to diagnose fever in a new setting. Therefore, we added a plot of the probability 
that ear thermometry is useful in a new population, that is, the probability that the NBt of ear 
thermometry is higher than the NBt of treat all or treat none in a new setting. The probability that 
using an ear thermometer for diagnosing fever is useful in a new setting is above 90% for risk 
thresholds between 0.39 and 0.86. Hence, if the perceived harm of a false negative is between 1.7 
and 0.2 times as large as the harm of a false positive, using an in-ear thermometer is a good 
diagnostic strategy. In contrast, if the perceived harm of a false negative is at least 9 times larger 
than the harm of a false positive (t≤0.1), reflecting that is very important not to miss cases of 
fever, the probability that using an in-ear thermometer is clinically useful in a new setting is less 
than 10%. In this case, it is better to err on the safe side and assume all patients have fever, or to 
use a rectal thermometer when possible.  
In the second example, the summary curve for the LR2 model (blue line) is higher than the 
summary curve of treat all (purple line) and treat none (black horizontal line) at all considered 
risk thresholds. However, the heterogeneity in the NBt of LR2 and treat all is very large, as 
reflected by the large prediction intervals. This is mainly caused by the large heterogeneity in the 
prevalence of malignancy across centers. The probability that LR2 has clinical utility to make 
treatment decisions in new centers is above 90% for risk threshold between 0.20 and 0.50. Hence, 
if the clinician’s judgement is that a false negative is between four and one times as harmful as a 
false positive, the LR2 model is a good tool to pre-operatively diagnose ovarian cancer. If the 
clinician believes that a false negative is 19 times as harmful as a false positive, the probability 
that the LR2 model is clinically useful in a new setting is still 70%. 
Extensions of the plot are straightforward: one may add the NBt curve of another diagnostic test, 
for example, temperature taken in the mouth or under the arm for the first example, and other 
diagnostic models for ovarian cancer in the second example. In addition, one may create a plot 
depicting NBt curves and the probability that the test/model is useful for a known prevalence in a 
new setting. Note that in this case, there will be no heterogeneity in the NBt curve for treat all, 
and the heterogeneity in the NBt of the test/model will only reflect heterogeneity in diagnostic 
accuracy (not heterogeneity in prevalence). 
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Figure 2. Decision curve for diagnosing fever using an in-ear thermometer. The bottom panel 
shows the probability that using an in-ear thermometer is clinically useful (i.e., has a higher NBt 
than treat all and treat none) in a randomly chosen new study. 
[insert figure 2 here] 
Figure 3. Decision curve for diagnosing ovarian malignancy using the LR2 model. The bottom 
panel shows the probability that using LR2 is clinically useful (i.e., has a higher NBt than treat 
all and treat none) in a randomly chosen new center. 
[insert figure 3 here] 
6. Discussion 
When heterogeneity in disease prevalence or diagnostic accuracy exists, the clinical usefulness of 
diagnostic tests and models differs between populations. We proposed to evaluate the Net Benefit 
(NBt) of a test or model across different studies or centers through a trivariate random-effects 
meta-analysis of sensitivity, specificity, and prevalence. This approach directly models the 
binomial distributions of true positive counts, true negative counts, and the number of diseased 
patients, and estimates the summary Net Benefit in a second step. Differences between settings 
are modelled through a product normal formulation of the between-study (or between-center) 
model of the logit sensitivity, logit specificity, and logit prevalence. This allows the user to 
specify realistic prior distributions for all elements of the variance-covariance matrix separately.  
Probability statements on the likely NBt in new settings provide crucial insights into the 
heterogeneity of the clinical utility. Using a Bayesian analysis, we sampled values for a new 
setting from the joint posterior distribution of sensitivity, specificity, and prevalence, to formulate 
statements on the likely NBt in a new setting. Examples include 95% prediction intervals for the 
NBt, 95% prediction intervals for the NBt for settings with a known prevalence, and the 
probability that a test/model is useful in a new setting (i.e., a higher NBt for the test/model than 
for default strategies of treating all or treating none). Heterogeneity in the clinical utility of the 
diagnostic test/model was demonstrated in two case studies. 
Heterogeneity in diagnostic accuracy is omnipresent: a systematic review estimated that 
heterogeneity affects 70% of published meta-analyses.
28
 However, even if the heterogeneity in 
diagnostic accuracy is negligible, heterogeneity in disease prevalence may still render the NBt of 
the test/model under investigation highly heterogeneous, as demonstrated in our case study on the 
diagnosis of ovarian cancer. The NBt of treating all patients without using a test/model is also 
heterogeneous across settings, whenever there is heterogeneity in the prevalence of the disease. 
This makes it very difficult to assess when a test/model is clinically useful, that is, superior to 
treat all or treat none: prediction intervals are very wide and swamp graphical depictions of the 
decision curves. Therefore, we proposed to calculate the posterior probability that the test/model 
is clinically useful in a new setting. 
Our case studies have demonstrated that the  probability of clinical usefulness in a new setting 
may be far from 0 or 1 at certain risk thresholds, effectively illustrating variability in the clinical 
usefulness of tests/models. This finding highlights once more the necessity of validating 
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diagnostic tests and risk prediction models in multiple relevant care settings to investigate 
heterogeneity in predictive performance and clinical utility, and assess generalizability and 
transportability.
1,2
 A practical approach is proposed in Box 1. If a risk prediction model has no 
clinical utility in certain settings, it may be worthwhile to update the model for these settings by 
recalibrating the model intercept or adjusting regression coefficients.
29,30
 It has been shown that 
perfectly calibrated models are never harmful.
13
 However, in practice, it may be difficult to 
obtain perfect calibration in all settings.
3
 
Box 1. Practical recommendations for validation. 
[insert Box 1 here] 
To get a more precise estimate of the clinical utility in a new setting, we suggest using prior 
knowledge on the prevalence in the target setting, if available. A similar idea was developed by 
Willis and colleagues,
31,32
 who proposed to use a priori information on the test positive rate and 
prevalence to exclude studies from the meta-analysis and obtain tailored estimates of test 
accuracy. Rather than excluding studies/centers from the meta-analysis, our approach uses all 
available information to explicitly model the correlations between prevalence and diagnostic 
accuracy. By subsequently conditioning on the known prevalence, we obtain a relevant summary 
NBt, a prediction interval, and the probability that the test/model will be useful in a new setting 
with the given prevalence. It is straightforward to reformulate our between-setting model of 
sensitivity, specificity, and prevalence in terms of test positive rates, positive predictive values, 
and negative predictive values. Such an alternative formulation may be of practical use, allowing 
assessments of clinical usefulness conditional on the test positive rate. Centers that wish to use 
the test/model under investigation may be more likely to know the test positive rate in their 
setting than the prevalence. 
As an alternative to the proposed random-effects meta-analysis of the NBt, you may consider 
combining the individual patient data from all centers or studies. One then computes the NBt 
based on the pooled dataset as if all observations came from the same setting. This approach is 
equivalent to computing a weighted average of the study or center-specific NBts, using the 
number of observations in each study or center as weights. As this approach fails to acknowledge 
any potential heterogeneity in clinical utility across settings, we do not recommend it. Kerr and 
colleagues proposed to calculate separate NBt-values for subpopulations, especially when 
diagnostic models have different predicted risk distributions.
4
 Although Kerr did not focus on 
subpopulations defined by different care settings, but rather on patient subgroups within one 
population (e.g., men and women), the idea may be applied to centers and studies as well. This 
approach recognizes heterogeneity in clinical utility, but a random-effects meta-analytic approach 
has the advantages of providing an overall summary estimate of NBt, and borrowing of strength 
for small populations. Indeed, estimates of the NBt may be unreliable for small centers or studies. 
Instead of performing a two-step approach (i.e. first performing a multivariable meta-analysis of 
diagnostic accuracy and prevalence and then, post-estimation, calculating the NBt) one could 
rather perform a random-effects meta-analysis of the study- or center-specific NBts directly. 
However, a number of difficulties are associated with this approach. First, it requires estimates of 
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the sampling variance of the NBt, for which no closed formula exists.
9,33
 Obtaining bootstrap 
standard errors for each study/center at each risk threshold is computationally intensive. Second, 
a between-study (or between-center) model of the NBt would need to be specified. Often, a 
normal distribution is chosen, but this may not be appropriate. At low thresholds asymmetric 
distributions may be expected, especially when the disease prevalence is high, as the NBt is 
bounded by 1 and the maximum attainable NBt equals the prevalence. At high risk thresholds, 
one may also expect an asymmetric distribution, one that is peaked near zero, with many 
studies/centers with a NBt well below zero. Especially in settings in which a diagnostic model 
discriminates well but is badly calibrated such that it overestimates the risk of an event, NBts 
below zero may occur at high risk thresholds.
13
 Lastly, the NBt estimates are not independent 
from their variance estimates. Typical variance-stabilizing functions, such as the logit and arcsine 
transformations, are not appropriate for the analysis of the NBt, which can take on any value 
between -∞ and 1. For these reasons, we prefer the proposed two-step approach over a direct 
meta-analysis of the NBt. 
The most important advantage of studying the clinical utility of a test/model, is that the NBt 
transcends traditional measures of discrimination and calibration, to incorporate consequences for 
clinical decision-making into the evaluation. The strength of our meta-analytic approach is that 
we explicitly address heterogeneity in clinical utility. In practice, a test/model may be widely 
recommended if the meta-analysis demonstrates clinical utility in a broad range of care settings. 
This generalist approach may be more feasible than a particularistic approach in which studies 
are conducted for each setting separately, and the use of the test/model is restricted to those 
centers in which utility has been demonstrated. A particularistic approach is often characterized 
by small sample sizes and high uncertainty in individual studies. 
This study has a number of limitations. For one, we merely investigate the presence of 
heterogeneity, but do not address the sources of heterogeneity. In the future, meta-regressions 
may be undertaken to incorporate study or center characteristics in the between-setting model as 
potential sources of heterogeneity. We assumed normality of the logit sensitivity, logit 
specificity, and logit prevalence. These are common assumptions,
15,19,34
 but future simulation 
studies could investigate whether our proposed approach is robust against violations of this 
assumption. Our analyses have shown that our method is sensitive to the choice of priors for the 
between-setting variance-covariance matrix, which is in accordance with previous studies.
20-22
 
Hence, we recommend picking priors based on available knowledge, or realistic weak priors, 
which is facilitated through the product normal formulation of the between-setting model.
21,23
 In 
case no prior knowledge is available, we suggest to use the priors specified in section 4.1. The 
presented case studies have only focused on the difference in the NBt between one test/model and 
the default strategies (treat all and treat none). The applications can easily be extended to 
compare the clinical utility of competing diagnostic tests or risk prediction models. 
A hindrance to the uptake of our method in practice may be that individual patient-data from all 
studies (or centers) is needed when a risk model is evaluated, as the classification then depends 
on the adopted risk threshold. One needs to evaluate for each risk threshold whether patients’ 
predicted risks fall below or above it. For binary tests, individual patient data is not needed, as 
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long as the numbers of diseased patients, true positives and false positives can be calculated from 
the reported outcomes.  
In summary, we have demonstrated a method to calculate the NBt based on a trivariate random-
effects meta-analysis of diagnostic accuracy and disease prevalence. The findings on our case 
studies suggest that the heterogeneity in clinical utility of a test/model across care settings should 
be quantified, before it is routinely implemented in practice. 
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 Table 1. True positives (r11), number with fever (n1), sensitivity, true negatives (r00), number 
without fever (n0), and specificity, for each temperature study included in the meta-analysis. 
First 
author 
r11j n1j Sensitivity r00j n0j Specificity 
Brennan 150 203 0.74 155 167 0.93 
Davis 9 18 0.50 46 48 0.96 
Green 8 9 0.89 12 12 1.00 
Greenes 53 109 0.49 193 195 0.99 
Hoffman 30 42 0.71 56 58 0.97 
Hooker 10 15 0.67 24 24 1.00 
Lanham 53 103 0.51 74 75 0.99 
Muma 48 87 0.55 136 136 1.00 
Nypaver 282 425 0.66 445 453 0.98 
Rhoads 7 27 0.26 38 38 1.00 
Stewart 57 59 0.97 20 20 1.00 
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Table 2. Summary sensitivity, specificity, and Net Benefit of ear thermometry to diagnose fever. 
 t=0.2 t=0.5 t=0.8 
Sensitivity  0.65 0.65 0.65 
Specificity 0.98 0.98 0.98 
    
NBt ear 0.30 0.29 0.27 
95% CrI 0.19 to 0.42  0.17 to 0.42 0.15 to 0.40 
95% PI 0.03 to 0.68 0.02 to 0.66 -0.05 to 0.66 
    
NBt ear | prev=.5 0.32 0.32 0.29 
95% CrI 0.24 to 0.40 0.23 to 0.39 0.21 to 0.37 
95% PI 0.12 to 0.47 0.10 to 0.46 0.04 to 0.44 
NBt: Net Benefit; CrI: credible interval; PI: prediction interval; t: risk threshold. 
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Table 3. Summary sensitivity, specificity, and Net Benefit of the LR2 model to diagnose ovarian 
malignancies pre-operatively. 
 t=0.05 t=0.1 t=0.5 
Sensitivity  0.95 0.90 0.63 
Specificity 0.68 0.80 0.95 
    
NBt LR2 0.27 0.25 0.16 
95% CrI 0.21 to 0.34 0.20 to 0.31 0.11 to 0.21 
95% PI 0.05 to 0.66 0.05 to 0.63 -0.01 to 0.52 
    
NBt LR2 | prev=0.15 0.13 0.12 0.06 
95% CrI 0.12 to 0.13 0.11 to 12 0.04 to 0.07 
95% PI 0.12 to 0.14 0.10 to 0.13 -0.01 to 0.08 
    
NBt LR2 | prev=0.35 0.32 0.30 0.19 
95% CrI 0.31 to 0.33 0.29 to 0.31 0.17 to 0.22 
95% PI 0.29 to 0.33 0.26 to 0.32 0.11 to 0.25 
NBt: Net Benefit; CrI: credible interval; PI: prediction interval; t: risk threshold 
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Table 4. Summary Net Benefit of treat all and the probability that ear thermometry will be useful 
in a new study. 
 t=0.2 t=0.5 t=0.8 
NBt treat all 0.33 -0.08 -1.69 
95% CrI 0.20 to 0.46 -0.29 to 0.13 -2.21 to -1.16 
95% PI -0.04 to 0.73 -0.65 to 0.57 -3.14 to -0.10 
    
NBt treat all | prev=0.5 0.38 0 -1.5 
    
P(ear useful) 0.44 0.97 0.95 
P(ear useful | prev=0.5) 0.34 1.00 0.99 
NBt: Net Benefit; CrI: credible interval; PI: prediction interval; t: risk threshold. 
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Table 5. Summary Net Benefit of treat all and the probability that LR2 will be useful in a new 
center. 
 t=0.05 t=0.1 t=0.5 
NBt treat all 0.26 0.22 -0.40 
95% CrI 0.20 to 0.34 0.15 to 0.30 -0.53 to -0.26 
95% PI 0.02 to 0.69 -0.03 to 0.66 -0.88 to 0.43 
    
NBt treat all | prev=0.15 0.11 0.06 -0.70 
NBt treat all | prev=0.35 0.32 0.28 -0.30 
    
P(LR2 useful) 0.69 0.78 0.95 
P(LR2 useful | prev=0.15) 1.00 1.00 0.93 
P(LR2 useful | prev=0.35) 0.75 0.91 1.00 
NBt: Net Benefit; CrI: credible interval; PI: prediction interval; t: risk threshold. 
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Box 1. Practical recommendations for validation. 
 
  
Recommendations for the validation of the predictive performance of a test/model: 
 Collect data from a broad range of clinical care settings in which the test/model is intended to be used.1 
 Assess the predictive performance of the test/model in terms of calibration and discrimination,1 
preferably using summary statistics from random-effects models.
14,15
 
 Assess the heterogeneity in predictive performance across settings, for example by using a random 
effects meta-analysis, and by providing 95% prediction intervals and probabilistic statements for the 
calibration and discrimination in new settings.
14,15
 
 Consider model recalibration or updating in settings where calibration is problematic.29 
Recommendations for the validation in terms of clinical utility: 
 Conduct a decision curve analysis and compare (for relevant harm to benefit ratios) the Net Benefit of 
the test/model to competing strategies (e.g., treat all, treat none),
9
 preferably using summary statistics 
from a random-effects model. 
 Assess the heterogeneity in clinical utility, by conducting a random-effects meta-analysis of Net Benefit 
and calculating 95% prediction intervals and probabilistic statements about the Net Benefit in new 
settings. 
o P(useful) is close to zero: advise against the test/model. Serious calibration issues are likely.  
o P(useful) is close to one: recommend the test/model. 
o P(useful) is close to 0.5: clinical utility is too variable to make a general recommendation; then 
 Investigate clinical usefulness in specific settings by conditioning on prevalence. 
Recommend the model settings in where utility is demonstrated. 
 Consider model recalibration or updating in settings where utility is not demonstrated.29 
 Caution is advised when the test/model has not been validated in a setting similar to 
yours. Findings may not generalize to your setting.
29
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Appendix 
Appendix Figure 1. Fisher prior for correlations (upper panel) and half-normal prior for 
between-setting variances (lower panel). 
[insert appendix figure 1 here] 
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Appendix Table 1. Normal priors for η1, λ20, and λ30, lognormal priors for between-setting 
variances, and Fisher priors for correlations, for the NBt analysis of LR2, based on posterior 
distributions obtained from the analysis of an external dataset. 
Parameter distribution mean sd 
t=0.05    
η1 Normal -1.04 0.23 
λ20 Normal 2.99 0.36 
λ30 Normal 1.37 1.73 
τ1
2 Lognormal -0.21 0.38 
τ2
2 Lognormal -1.08 1.09 
τ3
2 Lognormal -1.49 0.62 
Z (ρ12) Normal 0.07 0.49 
Z (ρ13) Normal -0.63 0.33 
Z (ρ23) Normal -0.41 0.41 
    
t=0.10    
η1 Normal -1.04 0.22 
λ20 Normal 2.31 0.31 
λ30 Normal 2.12 2.26 
τ1
2 Lognormal -0.28 0.38 
τ2
2 Lognormal -1.35 1.23 
τ3
2 Lognormal -1.21 0.68 
Z (ρ12) Normal -0.16 0.42 
Z (ρ13) Normal -0.74 0.33 
Z (ρ23) Normal -0.23 0.38 
    
t=0.50    
η1 Normal -1.05 0.24 
λ20 Normal 0.87 0.26 
λ30 Normal 4.12 0.65 
τ1
2 Lognormal -0.09 0.39 
τ2
2 Lognormal -0.99 0.69 
τ3
2 Lognormal -0.37 0.66 
Z (ρ12) Normal 0.50 0.33 
Z (ρ13) Normal -0.15 0.32 
Z (ρ23) Normal -0.55 0.35 
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Appendix Table 2. Sensitivity to choice of priors for the variance-covariance matrix for the ear 
thermometry case study. 
 t=0.2 t=0.5 t=0.8 
 Inverse 
Wishart 
Weak 
realistic 
Inverse 
Wishart 
Weak realistic 
Inverse 
Wishart 
Weak realistic 
Sensitivity  0.64 0.65 0.64 0.65 0.64 0.65 
Specificity 0.98 0.98 0.98 0.98 0.98 0.98 
       
NBt ear 0.30 0.30 0.29 0.29 0.25 0.27 
95% CrI 0.20 to 0.42 0.19 to 0.42 0.19 to 0.39 0.17 to 0.42 0.15 to 0.36 0.15 to 0.40 
95% PI 0.05 to 0.65 0.03 to 0.68 0.04 to 0.63 0.02 to 0.66 0.01 to 0.59 -0.05 to 0.66 
       
NBt ear | 
prev=.5 
0.32 0.32 0.31 0.32 0.28 0.29 
95% CrI 0.25 to 0.38 0.24 to 0.40 0.24 to 0.37 0.23 to 0.39 0.21 to 0.34 0.21 to 0.37 
95% PI 0.09 to 0.46 0.12 to 0.47 0.10 to 0.44 0.10 to 0.46 0.06 to 0.40 0.04 to 0.44 
       
NBt treat all 0.33 0.33 -0.07 -0.08 -1.67 -1.69 
95% CrI 0.23 to 0.44 0.20 to 0.46 -0.24 to 0.10 -0.29 to 0.13 -2.09 to -1.25 -2.21 to -1.16 
95% PI 0.02 to 0.66 -0.04 to 0.73 -0.55 to 0.44 -0.65 to 0.57 -2.91 to -0.35 -3.14 to -0.10 
       
P(ear useful) 0.31 0.44 1.00 0.97 0.98 0.95 
P(ear useful | 
prev=0.5) 
0.27 0.34 
1.00 
 
1.0 
0.99 
 
0.99 
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Appendix Table 3. Sensitivity to choice of priors for the variance-covariance matrix for the IOTA 
case study. 
 t=0.05 t=0.10 t=0.50 
 Inverse 
Wishart 
Weak 
realistic 
Inverse 
Wishart 
Weak 
realistic 
Inverse 
Wishart 
Weak 
realistic 
Sensitivity  0.95 0.95 0.90 0.90 0.64 0.63 
Specificity 0.66 0.68 0.79 0.80 0.95 0.95 
       
NBt LR2 0.31 0.27 0.29 0.25 0.18 0.16 
95% CrI 0.22 to 0.41 0.21 to 0.34 0.21 to 0.38 0.20 to 0.31 0.11 to 0.26 0.11 to 0.21 
95% PI 0.07 to 0.68 0.05 to 0.66 0.06 to 0.67 0.05 to 0.63 0.02 to 0.52 -0.01 to 0.52 
       
NBt LR2 | 
prev=.15 
0.13 0.13 0.11 0.12 0.05 0.06 
95% CrI 0.12 to 0.13 0.12 to 0.13 0.11 to 0.12 0.11 to 12 0.04 to 0.07 0.04 to 0.07 
95% PI 0.12 to 0.14 0.12 to 0.14 0.10 to 0.13 0.10 to 0.13 0.003 to 0.08 -0.01 to 0.08 
       
NBt LR2 | 
prev=.35 
0.32 0.32 0.30 0.30 0.19 0.19 
95% CrI 0.31 to 0.33 0.31 to 0.33 0.29 to 0.31 0.29 to 0.31 0.17 to 0.21 0.17 to 0.22 
95% PI 0.30 to 0.33 0.29 to 0.33 0.26 to 0.31 0.26 to 0.32 0.11 to 0.24 0.11 to 0.25 
       
NBt treat all 0.30 0.26 0.27 0.22 -0.32 -0.40 
95% CrI 0.21 to 0.41 0.20 to 0.34 0.17 to 0.38 0.15 to 0.30 -0.51 to -0.13 -0.53 to -0.26 
95% PI 0.04 to 0.71 0.02 to 0.69 -0.02 to 0.70 -0.03 to 0.66 -0.81 to 0.45 -0.88 to 0.43 
       
P(LR2 useful) 0.64 0.69 0.77 0.78 0.98 0.95 
P(LR2 useful | 
prev=0.15) 
1.00 1.00 1.00 1.00 0.98 0.97 
P(LR2 useful | 
prev=0.35) 
0.78 0.75 0.93 0.91 1.00 1.00 
 
